Progyny’s first quarter was met with a positive market response, driven by revenue and non-GAAP profit that exceeded Wall Street expectations. Management highlighted healthy member engagement and utilization rates within the company’s fertility benefits platform, with CEO Peter Anevski attributing the results to “continued discipline in managing the business,” and efficiencies in care management and service delivery. While overall sales volumes fell year on year, robust operating margin improvement and progress on new platform capabilities helped offset volume headwinds.
Is now the time to buy PGNY? Find out in our full research report (it’s free for active Edge members).
Progyny (PGNY) Q1 CY2026 Highlights:
- Revenue: $328.5 million vs analyst estimates of $326.2 million (1.4% year-on-year growth, 0.7% beat)
- Adjusted EPS: $0.50 vs analyst estimates of $0.44 (14.7% beat)
- Adjusted EBITDA: $56.58 million vs analyst estimates of $53.18 million (17.2% margin, 6.4% beat)
- The company slightly lifted its revenue guidance for the full year to $1.39 billion at the midpoint from $1.38 billion
- EBITDA guidance for the full year is $238 million at the midpoint, above analyst estimates of $232.5 million
- Operating Margin: 10.8%, up from 7.5% in the same quarter last year
- Sales Volumes fell 3.2% year on year (9.2% in the same quarter last year)
- Market Capitalization: $1.84 billion
While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Progyny’s Q1 Earnings Call
- Jailendra Singh (Truist Securities) asked about the composition of early sales commitments and increased RFPs from competitors’ clients; CEO Peter Anevski explained that most early commitments come from prior-year “not-nows,” while RFP uptick reflects broader interest, but no specific new themes were highlighted.
- Cameron (Jefferies, for Brian Tanquilut) inquired about drivers behind increased revenue per ART cycle; CFO Mark Livingston clarified the higher rate is due to a greater proportion of new clients in initial consultation phases, not a fundamental shift in ancillary product uptake.
- Michael Cherny (Leerink, via colleague) pressed for updates on the product pipeline and upsell expectations; Anevski said upsell activity remains positive but is not yet material to current-year guidance, and new investments are focused more on expanded capabilities than entirely new products.
- Scott Schoenhaus (KeyBanc) questioned whether new client cohorts are driving higher utilization; Anevski replied utilization is in line with expectations and mainly reflects industry mix, not elevated behavior in new cohorts.
- Sarah James (Cantor Fitzgerald) probed on the market’s preference for value-based care payment models; Anevski stated the current model is effective and client retention is driven by demonstrated savings, with no plans to shift to back-end savings or risk-based models.
Catalysts in Upcoming Quarters
In the coming quarters, our analysts will closely monitor (1) the pace of new client wins and the pull-through from the robust sales pipeline, (2) the impact of the Select product as small employer buying cycles reach their peak, and (3) the sustainability of margin gains from operational efficiencies and lower stock compensation. Progress on employer renewals and the continued health of member engagement rates will also be key indicators for tracking execution.
Progyny currently trades at $23.51, up from $19.16 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
